Form 144: 10,000 Ascendis ADS to be sold on NASDAQ via Merrill Lynch

Rhea-AI Filing Summary

Ascendis Pharma A/S submitted a Form 144 reporting a proposed sale of 10,000 American Depositary Shares through Merrill Lynch on NASDAQ with an aggregate market value of $1,913,224.99 and an approximate sale date of 08/13/2025.

The filing states the shares were acquired on 08/13/2025 by warrant exercise from Ascendis Pharma A/S, with cash payment. Total shares outstanding are listed as 60,454,589. The filer reports no securities sold in the past three months and attests they do not know of any undisclosed material adverse information regarding the issuer.

Insights

Financial Analyst

TL;DR: Routine disclosure of a proposed insider sale; size appears immaterial to capitalization.

The Form 144 documents a planned sale of 10,000 ADS valued at $1.913M executed through Merrill Lynch on NASDAQ. With 60,454,589 shares outstanding, the position disclosed is small relative to the issuer's capital base and the filing notes no other sales in the prior three months. This notice provides market transparency but, standing alone, contains no operating or financial information that materially alters Ascendis Pharma's reported fundamentals.

Corporate Governance Expert

TL;DR: Compliance-focused filing showing a post-warrant liquidity event; disclosure meets Rule 144 informational requirements.

The notice specifies acquisition by warrant exercise and cash payment on the same date as the proposed sale, names the executing broker, and includes the filer’s attestation regarding material nonpublic information. These elements align with standard Rule 144 compliance and improve transparency for investors, but do not indicate governance issues or material company events by themselves.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	10000	1913224.99	60454589	08/13/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
American Depositary Shares	08/13/2025	Warrant exercise	Ascendis Pharma A/S			10000	08/13/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Ascendis Pharma (ASND) disclose?

The form discloses a proposed sale of 10,000 ADS valued at $1,913,224.99 through Merrill Lynch on NASDAQ with an approximate sale date of 08/13/2025.

How were the 10,000 ADS acquired according to the filing?

The shares were acquired on 08/13/2025 by warrant exercise from Ascendis Pharma A/S and paid for in cash.

How many Ascendis shares are outstanding per the Form 144?

The filing lists 60,454,589 shares outstanding.

Does the filer report other sales in the prior three months?

The filing states Nothing to Report for securities sold during the past three months.

Does the filer confirm possession of any undisclosed material information?

The filer attests they do not know any material adverse information regarding the issuer that has not been publicly disclosed.